Axovant Sciences Ltd (NYSE:AXON)‘s stock had its “hold” rating restated by investment analysts at Robert W. Baird in a research report issued to clients and investors on Wednesday, November 1st. They currently have a $6.00 target price on the biotechnology company’s stock. Robert W. Baird’s price target suggests a potential upside of 12.36% from the company’s previous close.
Several other analysts have also issued reports on the stock. BidaskClub lowered shares of Axovant Sciences from a “sell” rating to a “strong sell” rating in a research report on Friday, September 15th. Evercore ISI initiated coverage on shares of Axovant Sciences in a research report on Friday, September 8th. They issued an “outperform” rating and a $30.00 price target for the company. Zacks Investment Research upgraded shares of Axovant Sciences from a “hold” rating to a “strong-buy” rating and set a $8.00 price target for the company in a research report on Monday, October 9th. Chardan Capital reiterated a “sell” rating and issued a $3.00 price target on shares of Axovant Sciences in a research report on Saturday, September 23rd. Finally, HC Wainwright reissued a “buy” rating on shares of Axovant Sciences in a report on Thursday, October 19th. Four investment analysts have rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the company’s stock. Axovant Sciences has a consensus rating of “Hold” and an average price target of $14.13.
Shares of Axovant Sciences (NYSE:AXON) opened at $5.34 on Wednesday. Axovant Sciences has a 12 month low of $4.60 and a 12 month high of $27.98. The company has a current ratio of 6.01, a quick ratio of 6.01 and a debt-to-equity ratio of 0.25.
Axovant Sciences (NYSE:AXON) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.12).
COPYRIGHT VIOLATION WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/11/12/robert-w-baird-reiterates-hold-rating-for-axovant-sciences-ltd-axon.html.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Oppenheimer & Co. Inc. bought a new position in shares of Axovant Sciences in the third quarter worth about $101,000. Bank of America Corp DE grew its holdings in Axovant Sciences by 38.9% during the 1st quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 2,072 shares in the last quarter. Legal & General Group Plc grew its holdings in Axovant Sciences by 20.2% during the 2nd quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock worth $162,000 after acquiring an additional 1,168 shares in the last quarter. American International Group Inc. grew its holdings in Axovant Sciences by 7.1% during the 1st quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock worth $225,000 after acquiring an additional 998 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in Axovant Sciences by 38.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock worth $233,000 after acquiring an additional 2,789 shares in the last quarter.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.